Susquehanna International Group, LLP Cyma Bay Therapeutics, Inc. Call Options Transaction History

Susquehanna International Group, LLP

$560 Billion
Q3 2024

Call Options

25 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q4 2023 Feb 14, 2024	BUY	$12.63 - $24.47 $7.46 Million - $14.5 Million	590,600 Added 305.54%	783,900 $18.5 Million
Q3 2023 Nov 14, 2023	BUY	$10.86 - $17.62 $865,542 - $1.4 Million	79,700 Added 70.16%	193,300 $2.88 Million
Q2 2023 Aug 11, 2023	SELL	$7.47 - $10.95 $481,068 - $705,180	-64,400 Reduced 36.18%	113,600 $1.24 Million
Q1 2023 May 16, 2023	BUY	$5.88 - $9.59 $463,344 - $755,692	78,800 Added 79.44%	178,000 $1.55 Million
Q4 2022 Feb 14, 2023	BUY	$3.22 - $6.27 $130,088 - $253,307	40,400 Added 68.71%	99,200 $621,000
Q3 2022 Nov 14, 2022	SELL	$2.77 - $4.25 $52,353 - $80,325	-18,900 Reduced 24.32%	58,800 $206,000
Q2 2022 Aug 15, 2022	SELL	$1.72 - $3.39 $56,416 - $111,192	-32,800 Reduced 29.68%	77,700 $229,000
Q1 2022 May 16, 2022	SELL	$2.77 - $3.64 $235,727 - $309,764	-85,100 Reduced 43.51%	110,500 $344,000
Q4 2021 Feb 14, 2022	BUY	$3.23 - $4.6 $31,008 - $44,160	9,600 Added 5.16%	195,600 $661,000
Q3 2021 Nov 15, 2021	BUY	$3.47 - $4.42 $59,337 - $75,582	17,100 Added 10.12%	186,000 $679,000
Q2 2021 Aug 11, 2021	BUY	$3.94 - $4.92 $219,852 - $274,536	55,800 Added 49.34%	168,900 $736,000
Q1 2021 May 17, 2021	SELL	$4.23 - $6.55 $318,519 - $493,215	-75,300 Reduced 39.97%	113,100 $513,000
Q4 2020 Feb 16, 2021	SELL	$5.73 - $9.03 $884,139 - $1.39 Million	-154,300 Reduced 45.02%	188,400 $1.08 Million
Q3 2020 Nov 16, 2020	BUY	$3.32 - $7.24 $406,368 - $886,176	122,400 Added 55.56%	342,700 $2.48 Million
Q2 2020 Aug 14, 2020	BUY	$1.41 - $4.25 $245,340 - $739,500	174,000 Added 375.81%	220,300 $769,000
Q4 2019 Feb 14, 2020	SELL	$1.33 - $5.93 $618,583 - $2.76 Million	-465,100 Reduced 90.95%	46,300 $91,000
Q3 2019 Nov 14, 2019	BUY	$5.12 - $7.21 $323,072 - $454,951	63,100 Added 14.08%	511,400 $2.62 Million
Q2 2019 Aug 14, 2019	BUY	$6.05 - $13.66 $2.31 Million - $5.22 Million	382,000 Added 576.17%	448,300 $3.21 Million
Q1 2019 May 15, 2019	BUY	$8.16 - $13.42 $326,400 - $536,800	40,000 Added 152.09%	66,300 $880,000
Q4 2018 Feb 14, 2019	SELL	$6.54 - $11.74 $14,388 - $25,828	-2,200 Reduced 7.72%	26,300 $207,000
Q3 2018 Nov 14, 2018	SELL	$10.88 - $14.52 $141,440 - $188,760	-13,000 Reduced 31.33%	28,500 $316,000
Q2 2018 Aug 14, 2018	SELL	$10.66 - $14.38 $782,444 - $1.06 Million	-73,400 Reduced 63.88%	41,500 $557,000
Q1 2018 May 15, 2018	BUY	$9.0 - $15.16 $907,200 - $1.53 Million	100,800 Added 714.89%	114,900 $1.49 Million
Q4 2017 Feb 14, 2018	SELL	$7.67 - $9.31 $96,642 - $117,306	-12,600 Reduced 47.19%	14,100 $130,000
Q3 2017 Nov 14, 2017	BUY	$5.95 - $8.26 $158,865 - $220,542	26,700	26,700 $215,000

Others Institutions Holding CBAY

# of Institutions

Shares Held

1.82M

Call Options Held

Put Options Held

View Full List

About CymaBay Therapeutics, Inc.

Ticker CBAY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 84,677,904
Description
CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar (MBX-8025), a selective agonist of peroxisome proliferator activated receptor delta that is in phase III clinical study for the treatments of pri...

More about CBAY

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

News

Stay updated on Susquehanna International Group, LLP with notifications on news.

Account